Application of Multiplex Branched Dna Liquidchip Technology (Mbl) for Optimal Selection of Chemotherapy in Elderly Patients

Yang, Chengwei; Zhou, Qinghua; He, Jinzhi; Yang, Huiyi; Luo, Xiaodi; Xu, Jianbing

doi:10.1016/j.jgo.2014.06.032

Cited by 3 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mRNA expression levels of ERCC1, RRM1, TUBB3, TYMS and TOP2A in the breast cancer tissues were measured simultaneously using multiplex branched DNA liquidchip (MBL) technology (Guangzhou SurExam Bio-Tech Co., Ltd.) as previously reported ( 14 – 16 ). The main steps in this analysis were as follows: i) Samples were lysed in buffer at 56°C for 2 h; ii) the lysed product was added to each well of a 96-well plate containing blocking reagent, target gene-specific probe sets and capture beads; iii) the plate was sealed, and then incubated for 18 h at 54°C on a shaker, followed by the addition of hybridization mixture; iv) the unbound mRNA and other debris in each well were removed by washing three times with buffer; v) signals for bound target mRNA were amplified with streptavidin-phycoerythrin at 50°C for 30 min; vi) the fluorescence value of each sample was measured and analyzed using the Luminex ® 200 system™ (Luminex Corporation) to determine the mRNA expression level of each gene.…”

Section: Methodsmentioning

confidence: 99%

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study

Li¹,

Sun²,

Huang³

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study

Li¹,

Sun²,

Huang³

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

“…We believe our results is reliable because MBL is suitable for various sample types and is widely used in clinical diagnosis. [ 7 , 24 , 25 ]…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, the results of this study are reliable, because MBL technology is a mature gene detection technology which has been widely applied in clinical diagnosis and individualized treatment. [ 7 , 24 , 25 ] Thirdly, coexpression and negative correlation of those genes are not verified by the public bulk RNA-seq data for breast cancer cohorts or even cell lines. The bulk RNA-seq data of breast cancer cohorts and cell lines will be downloaded from the website portals: The Cancer Genome Atlas (TCGA), The Genotype-tissue Expression Project (GTEx), Cancer Cell Line Encyclopedia (CCLE), and International Cancer Genome Consortium (ICGC), to further confirm genes interactions and clinical practicality in the subsequent study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer

Sun

Huang

et al. 2021

Medicine

View full text Add to dashboard Cite

Excision repair cross complementing 1 ( ERCC1 ), ribonucleotide reductase M1 ( RRM1 ), β-tubulin III ( TUBB3 ), thymidylate synthetase ( TYMS ), and topoisomerase IIα ( TOP2A ) genes have been shown to be associated with the pathogenesis and prognosis of various types of carcinomas; however, their roles in breast cancer have not been fully validated. In this study, we evaluated the correlations among these biomarkers and the associations between their expression intensity and the clinicopathological characteristics to investigate whether the above genes are underlying biomarkers for patients with breast cancer. Ninety-seven tissue specimens collected from breast cancer patients. The expression levels of these biomarkers were measured by the multiplex branched DNA liquidchip (MBL) technology and clinicopathological characteristics were collected simultaneously. The expression levels of ERCC1 , TUBB3 , TYMS , and TOP2A were significantly associated with the characteristics of menopausal status, tumor size, lymph node metastasis, hormone receptor status, triple-negative status, Ki-67 index, and epidermal growth factor receptor. The expression intensity of ERCC1 negatively associated with that of TUBB3 and TYMS , and positively associated with that of RRM1 . The expression intensity of TOP2A positively associated with that of TYMS . Hierarchical clustering analysis and difference test indicated that breast cancer with higher levels of TUBB3 , TYMS , and TOP2A , as well as lower levels of ERCC1 and RRM1 tended to have higher histological grade and Ki-67 index. Our studies showed that ERCC1 , TYMS , TUBB3 , and TOP2A may be potential biomarkers for prognosis and individualized chemotherapy guidance, while there may be interactions between ERCC1 and RRM1 , or TUBB3 , or TYMS , as well as between TOP2A and TYMS in pathogenesis and development of breast cancer.

show abstract

“…A multiplex branched DNA liquidchip (MBL) technology (Guangzhou SurExam Bio-Tech Co., Ltd., China) was used for quantitative determination of all the genes at the mRNA level in the tissue samples simultaneously as previously reported [3, 22, 23]. Briefly, the tissue samples were lysed in buffer at 56 °C for 2 h. The lysed product was transferred to a 96-well plate in which blocking reagent, capture beads and target gene-specific probe sets were included, and then incubated at 55 °C overnight on a shaker, followed by adding the hybridization mixture.…”

Section: Methodsmentioning

confidence: 99%

Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundIndividualized therapeutic regimen is a recently intensively pursued approach for targeting diseases, in which the search for biomarkers was considered the first and most important. Thus, the goal of this study was to investigate whether the UGT1A1, ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A genes are underlying biomarkers for gastric cancer, which, to our knowledge, has not been performed.MethodsNinety-eight tissue specimens were collected from gastric cancer patients between May 2012 and March 2015. A multiplex branched DNA liquidchip technology was used for measuring the mRNA expressions of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A. Direct sequencing was performed for determination of UGT1A1 polymorphisms. Furthermore, correlations between gene expressions, polymorphisms and clinicopathological characteristics were investigated.ResultsThe expressions of TYMS, TUBB3 and STMN1 were significantly associated with the clinicopathological characteristics of age, gender and family history of gastric cancer, but not with differentiation, growth patterns, metastasis and TNM staging in patients with gastric cancer. No clinical characteristics were correlated with the expressions of ERCC1, BRCA1, RRM1 and TOP2A. Additionally, patients carrying G allele at −211 of UGT1A1 were predisposed to developing tubular adenocarcinoma, while individuals carrying 6TAA or G allele respectively at *28 or −3156 of UGT1A1 tended to have a local invasion.ConclusionsThe UGT1A1 polymorphism may be useful to screen the risk population of gastric cancer, while TYMS, TUBB3 and STMN1 may be potential biomarkers for prognosis and chemotherapy guidance.Electronic supplementary materialThe online version of this article (doi:10.1186/s12876-016-0561-x) contains supplementary material, which is available to authorized users.

show abstract

Application of Multiplex Branched Dna Liquidchip Technology (Mbl) for Optimal Selection of Chemotherapy in Elderly Patients

Cited by 3 publications

References 3 publications

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study

Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study

Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer

Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer

Contact Info

Product

Resources

About